Skip to main content
Smart Investors Daily
LE

NASDAQ · LEGN

Legend Biotech Corporation

Healthcare · Biotechnology

$16.10

Down-$0.15 (-0.92%)

Updated Nov 20, 2026, 2:38 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.12B
P/E ratio
-6.5
Dividend yield
0.00%
52-week range
$15.75 – $37.50
Volume
2.37M
Avg. volume
1.71M

Price performance · LEGN

LEGN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

LEGN closed at $16.10 after 21 trading sessions, down 14.81% for the selected period.

Last close
$16.10
Period change
-14.81%
Period low
$15.99
Period high
$24.29
Daily close
View OHLC price history
LEGN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$16.30$16.42$15.73$16.102.37M
Nov 18, 2026$16.12$17.057$16.03$16.252.15M
Nov 17, 2026$16.14$16.50$15.75$16.113.03M
Nov 16, 2026$17.36$17.50$15.97$15.992.83M
Nov 13, 2026$18.46$18.61$17.385$17.503.03M
Nov 12, 2026$19.10$19.13$17.8573$18.544.45M
Nov 11, 2026$20.67$20.73$18.87$19.544.42M
Nov 10, 2026$21.33$22.85$19.7615$20.416.38M
Nov 9, 2026$23.80$24.42$22.88$24.292.04M
Nov 6, 2026$23.09$23.74$22.565$23.401.77M
Nov 5, 2026$22.77$23.98$22.215$22.543.23M
Nov 4, 2026$22.44$23.72$21.70$22.773.16M
Nov 3, 2026$21.22$21.665$21.12$21.481.64M
Nov 2, 2026$21.78$21.79$20.99$21.101.13M
Oct 30, 2026$22.12$22.42$21.34$21.632.19M
Oct 29, 2026$22.55$22.955$22.04$22.302.37M
Oct 28, 2026$21.30$22.98$20.911$22.532.36M
Oct 27, 2026$20.39$21.665$19.9082$21.562.12M
Oct 26, 2026$19.17$21.04$19.075$20.392.37M
Oct 23, 2026$18.87$19.29$18.44$19.27979.58K
Oct 22, 2026$18.42$18.97$18.40$18.901.2M

Latest LEGN news

The latest Smart Investors Daily articles mentioning LEGN.

LEGN research

Overview

Company profile and research snapshot.

Company profile

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$60.67
Implied upside
—
Analysts
24
LEGN recent ratings
DateFirmRatingTarget
Nov 16, 2026Evercore ISI GroupIn-Line—
Nov 11, 2026RBC CapitalOutperform—
Nov 11, 2026BarclaysOverweight—
Nov 11, 2026Morgan StanleyOverweight—
Nov 11, 2026OppenheimerPerform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Is Legend Biotech (LEGN) Reasonable After CARVYKTI Sales Growth?

Legend Biotech has had a rough stretch in the market, with a steep multi year share price drop sitting alongside growing interest in its cell therapy franchise. That mix raises a straightforward question for you as an investor: is the current US$19.54 price adequately supported by the company’s sales profile? The stock has fallen 69.3% over the past 3 years, which puts the focus squarely on whether the underlying revenue base can justify even this lower level. Recent updates around CARVYKTI...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.